BM Everett, JG MacFadyen, T Thuren,
P Libby… - Journal of the American …, 2020 - jacc.org
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab
significantly reduces the first major adverse cardiovascular event in patients with prior …